Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies - Minami, Hironobu; Doi, Toshihiko; Toyoda, Masanori; Imamura, Yoshinori; Kiyota, Naomi; Mitsuma, Ayako; Shimokata, Tomoya; Naito, Yoichi; Matsubara, Nobuaki; Tajima, Takeshi; Tokushige, Kota; Ishihara, Kae; et al. (Cancer science, 2021)
Keywords: Adult; Adverse events; Aged; Alkaline phosphatase; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - therapeutic use; Antitumor activity; Apoptosis; Cancer therapies; Cell death; clinical trial; Dose-Response Relationship, Drug; Drug dosages; Female; Hepatocellular carcinoma; humanized monoclonal antibody; Humans; Immune Checkpoint Inhibitors - therapeutic use; Immunoglobulin G; immunotherapy; Japan; Lung diseases; Lymphocytes; Male; Maximum Tolerated Dose; Metastasis; Middle Aged; Monoclonal antibodies; Neoplasms - drug therapy; Original; Patients; PD-1 protein; Pharmacokinetics; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Safety; Statistical analysis; Toxicity; Transitional cell carcinoma; Tumors; Japan; clinical trial; maximum tolerated dose; humanized monoclonal antibody; Japan; immunotherapy